How much is netwealth worth?
As of July 17, 2026, Neurocrine Biosciences maintains a market capitalization of approximately 17.19 billion dollars. This valuation represents the total market value of the company's outstanding shares as perceived by public equity markets. Over the preceding twelve months, the company's market capitalization has experienced an increase of approximately 21.5 percent, reflecting growing investor confidence in its pharmaceutical pipeline and therapeutic offerings. Market capitalization acts as a key indicator of the firm's size within the biotechnology sector, allowing investors to assess its scale relative to other pharmaceutical competitors. As a publicly traded entity, this market-assigned value fluctuates continuously during trading hours based on real-time changes in share price, investor sentiment, and financial reports that detail the company's progress in clinical trials and commercial operations in the healthcare market.
Related FAQs
Nexi operates as a prominent European pay-tech and digital payments company, generating its substantial revenues through merchant acquiring, issuing services, and digital banking solutions.
NexBank has a rich organizational history spanning over a century, tracing its ultimate lineage back to 1922 when it was originally established as the Terrell Federal Savings and Loan Association in Terrell, Texas.
Neurocrine Biosciences, Inc. is a prominent biopharmaceutical enterprise focused on discovering, developing, and commercializing transformative treatments for serious neurological, neuroendocrine, and neuropsychiatric disorders.
Prominent Indian entrepreneur and investor Nikhil Kamath, co-founder of Zerodha, has participated in various funding rounds supporting Ather Energy, one of India's leading electric vehicle scooter manufacturers.